Format

Send to:

Choose Destination
See comment in PubMed Commons below
Expert Rev Anticancer Ther. 2012 May;12(5):555-65. doi: 10.1586/era.12.25.

Cetuximab in metastatic colorectal cancer.

Author information

  • 1The Queen Elizabeth Hospital and Discipline of Medicine University of Adelaide, 28 Woodville Road, Woodville South, SA 5011, Australia.

Abstract

Management of metastatic colorectal cancer has evolved in the last 10 years, with the availability of targeted therapies resulting in improvement in quality of life and overall survival. Cetuximab is a chimeric monoclonal antibody that binds to the EGF receptor, and the net effects are inhibition of tumor growth, invasion, angiogenesis and metastasis. Cetuximab binding to the EGF receptor is also known to augment the effects of chemotherapy and radiotherapy. Only tumors expressing wild-type KRAS respond to cetuximab and improvements in progression-free survival and overall survival are seen, whereas patients with mutant KRAS are considered to be resistant. Cetuximab is currently available worldwide for use as monotherapy or in combination with chemotherapy in first-, second- or third-line settings in metastatic colorectal cancer patients with wild-type KRAS.

PMID:
22594891
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Write to the Help Desk